Last reviewed · How we verify
NCT07519616
Effect of Escherichia Coli 5C (Colipral®) on Post-Colonoscopy Gastrointestinal Symptoms
NA trial testing Colipral® in Post-Colonoscopy Gastrointestinal Symptoms in 160 participants. Not yet recruiting.
30 September 2026
Quick facts
| Lead sponsor | Liaquat University of Medical & Health Sciences |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 160 |
| Start date | 27 April 2026 |
| Primary completion | 30 September 2026 |
| Estimated completion | 30 October 2026 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Colipral®
- Placebo
Conditions studied
- Post-Colonoscopy Gastrointestinal Symptoms — all drugs for Post-Colonoscopy Gastrointestinal Symptoms →
Sponsor
Liaquat University of Medical & Health Sciences
Who can join
Adults 18 to 80, any sex, with Post-Colonoscopy Gastrointestinal Symptoms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial will evaluate the efficacy and safety of Escherichia coli 5C (Colipral®) in adult patients undergoing diagnostic colonoscopy. Participants will be randomized in a 1:1 ratio to receive either Colipral® or placebo for 14 days immediately after colonoscopy. The study aims to determine whether Colipral® reduces post-colonoscopy gastrointestinal symptoms compared with placebo, using validated symptom and stool assessment tools, patient-reported global improvement, and safety monitoring.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07519616
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Liaquat University of Medical & Health Sciences trials
Trials by the same sponsor.
- NCT07536698 — Co-supplementation With Bifidobacterium Longum W11 and Colopectin for Maintenance Therapy in Children With Functional Co · NA · not yet recruiting
- NCT07502807 — Effect of Neurofast® Supplementation on Anxiety and Cardiovascular Outcomes in the Psycho-Cardio Phenotype Adults · NA · not yet recruiting
- NCT07494279 — Efficacy of Nigella Sativa (Nisatol®) in Women With Borderline Blood Pressure Values or a Non-Dipper Blood Pressure Phen · NA · not yet recruiting
- NCT07474831 — Evaluation of the Ability of Lactobacillus Crispatus CRP21 to Reduce the Incidence of Recurrent Bacterial Vaginosis · NA · not yet recruiting
- NCT07465575 — Berberine Phytosome for Signs and Symptoms of Polycystic Ovary Syndrome (PCOS) · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07519616 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Liaquat University of Medical & Health Sciences
- Last refreshed: 9 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07519616.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing